Abstract
Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Judson, I., Calvert, A., Gore, M. et al. Phase II trial of trimelamol in refractory ovarian cancer. Br J Cancer 63, 311–313 (1991). https://doi.org/10.1038/bjc.1991.72
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.72
- Springer Nature Limited